MRC Technology and AICR Partnership Reports Success for Cancer Research
News Feb 27, 2013
MRC Technology has reported successful results from the first year of its agreement with the Association for International Cancer Research (AICR).
The partnership enables AICR to take advantage of MRC Technology’s IP management, technology transfer, and drug discovery expertise, to help maximize the health benefits and revenue derived from AICR-funded research.
Over the year, MRC Technology’s experts reviewed and monitored 25 priority projects from AICR’s overall portfolio, advising on development and commercialization as appropriate.
For three of these projects, MRC Technology negotiated revenue share agreements on behalf of AICR with the universities holding the grants.
Each of these agreements reflects the value of the support given by AICR towards the success and commercialization of the research.
Mike Johnson, MRC Technology’s Director of Corporate Partnerships commented: “The success of this relationship is based on the ability of MRC Technology to add value to AICR’s mission, ensuring that research funded by the organization creates potential new health benefits wherever possible. We look forward to continuing our work with AICR, and to building similar partnerships with other charities and universities.”
Dr Helen Rippon, Head of Science at AICR commented, “We very much value our partnership with MRC Technology, and recognize their expertise in managing and commercializing IP. We are a small team at AICR, and only through our partnership with MRC Technology can we ensure that opportunities are not missed for AICR-funded research to be steered towards patient benefit. We have found their open, honest and regular communication and flexibility to be of great benefit through the past year. We look forward to continuing the relationship and further realizing returns on AICR-funded research for people affected by cancer.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018